The Journal of Clinical Psychiatry Podcast explores the science, practice, and human side of mental health care. Hosted by Dr. Ben Everett, Senior Scientific Director at Physicians Postgraduate Press, the series brings together leading voices in psychiatry, neuroscience, and behavioral medicine to discuss the evidence shaping clinical care today.
Each episode features thoughtful conversations with JCP authors, academic experts, and frontline clinicians exploring disorders across the mental health continuum, from schizophrenia and mood disorders to anxiety, depression, and sleep-related conditions. By bridging research and real-world practice, the podcast delivers insights that empower psychiatrists, nurse practitioners, physician associates, and primary care clinicians to deliver better care for patients with mental illness.
Insightful. Evidence-based. Human-centered.
Advertise on The Journal of Clinical Psychiatry Podcast
Advertise on The Journal of Clinical Psychiatry Podcast to promote your brand to thousands of podcast listeners
Unlock The Journal of Clinical Psychiatry Podcast podcast Email contact info, Listeners & Audience details
Email contact information
Direct podcast contact details
Listeners
Audience numbers & engagement insights
Audience details
Podcast Insights
Podcast episodes
Check latest episodes from The Journal of Clinical Psychiatry Podcast podcast
Treating Alzheimer’s Agitation, Not Just Quieting It with Pierre N. Tariot, MD
2026/11/03
In this episode of The JCP Podcast, host Dr. Ben Everett speaks with Dr. Pierre N. Tariot, director of the Banner Alzheimer’s Institute and research professor of psychiatry at the University of Arizona College of Medicine. Dr. Tariot, who has studied agitation and dementia for nearly four decades, chaired an expert consensus panel behind a new report on recognizing, assessing, and treating agitation in Alzheimer’s disease, published in The Primary Care Companion for CNS Disorders.
With most people living with dementia managed in primary care and long waits to see dementia specialists, the panel’s central message is that the goal is not a quieter patient but a safer, more engaged one. Dr. Tariot reviews decades of trial data on carbamazepine, divalproex, atypical antipsychotics, quetiapine, and trazodone, and explains why sedation should not be mistaken for efficacy. The conversation covers ruling out reversible causes, nonpharmacologic approaches including the DICE framework, practical assessment tools, the two FDA-approved therapies, brexpiprazole and dextromethorphan-bupropion, cross-tapering from off-label agents, and emerging treatments on the horizon.
🎯 KEY EPISODE HIGHLIGHTS:
🪞 THE INTRUDER IN THE MIRROR [21:30]
“She saw herself in the mirror when she went into her room and thought that image was an intruder and that she needed to defend herself.”
A home-visit case shows how a careful look at the environment can resolve nightly agitation without any medication at all.
🗣️ AGITATION AS COMMUNICATION [22:36]
“They're communicating that their needs are not being met.”
Reframing disruptive behavior as an expression of unmet needs guides clinicians toward pain, sensory deficits, and other treatable contributors before reaching for a prescription.
🤝 THE MOST ESSENTIAL ELEMENT [37:30]
“If I were to identify the most essential element for therapeutic success, is the willingness of the medical practitioner to engage with the patient and family on this.”
Sustained clinician engagement lowers family anxiety, builds tolerance for setbacks, and anchors a target-symptom approach to treatment over time.
CHAPTERS:
00:00 – Introduction and Dr. Tariot’s Path Into Agitation Research
04:31 – Why This Consensus Report Was Written for Primary Care
07:15 – Four Decades of Trials: Carbamazepine, Divalproex, and the Atypicals
12:17 – Primary Care as the Front Line: Lessons From Depression
16:08 – Sedation Is Not Efficacy
19:33 – Talking With Care Partners and Identifying Unmet Needs
23:52 – Revisiting the Evidence for Quetiapine and Trazodone
28:09 – Two FDA-Approved Options: Brexpiprazole and Dextromethorphan-Bupropion
32:09 – Older Versus Newer Agents and the Boxed Warning
35:03 – Preparing Patients and Families for the Primary Care Visit
40:20 – Measuring Agitation: IPA Criteria, DICE, and Practical Assessment Tools
45:00 – Switching From Off-Label Agents: Cross-Tapering and Practical Barriers
48:30 – What’s Next: Novel Mechanisms, Disease Modification, and One Takeaway
LINKS:
Full transcript and show notes:
https://www.psychiatrist.com/jcp/ep28-treating-alzheimers-agitation-not-just-quieting-pierre-n-tariot/
The Journal of Clinical Psychiatry
https://www.psychiatrist.com/jcp/
Publisher of peer-reviewed research discussed in this episode.
Targeted Treatment of Agitation in Alzheimer’s Dementia: Prioritizing Function and Safety Over Sedation and Other Serious Harms
https://www.psychiatrist.com/pcc/targeted-treatment-agitation-alzheimers-dementia/
The consensus panel report chaired by Dr. Tariot, published in The Primary Care Companion for CNS Disorders.
Dr. Pierre N. Tariot – LinkedIn
https://www.linkedin.com/in/pierre-tariot-13557ba/
The Primary Care Companion for CNS Disorders
https://www.psychiatrist.com/pcc/
#AlzheimersDisease #AgitationInDementia #PrimaryCare #GeriatricPsychiatry #Psychopharmacology
Bonus Episode: Psychedelic Research Inside an Academic Medical Center with Scott Thompson, PhD
2026/10/27
In this bonus episode, Dr. Ben Everett speaks with Scott Thompson, PhD, professor of psychiatry at the University of Colorado School of Medicine, where he directs the Novel Therapeutics in the Brain and Behavior Innovation Center and leads the Psychedelic Public Policy Partnership. Drawing on more than 40 years of synaptic research, Dr. Thompson describes how an unexpected finding on SSRI action led his lab to show in mice that psilocybin's antidepressant-like effects persisted even when the 5-HT2A receptor was blocked, and what that finding means for the question of whether the psychedelic experience itself is the medicine.
As psychedelic compounds advance through late-stage development, clinicians face open questions about mechanism, trial design, safety, and access. This conversation covers functional unblinding and the search for objective endpoints such as anhedonia, what it takes to run Schedule I research inside an academic medical center, and real-world outcome and safety data from more than 2,300 people who received regulated psilocybin services in Colorado and Oregon. Dr. Thompson also discusses the role of psychotherapy, the evidence on microdosing, and phase III programs including Definium's DT120 LSD formulation and Beckley Atai's intranasal 5-MeO-DMT.
KEY EPISODE HIGHLIGHTS: A SUPERCHARGED SSRI [45:30]
“psychedelics do what SSRIs do. They just do it more potently and more quickly.”
Dr. Thompson's working hypothesis frames psychedelics as faster, stronger versions of a mechanism clinicians already use every day, which shapes how his lab tests whether the trip is required.
A DOSE CEILING IN REAL-WORLD DATA [27:31]
“people who got doses of psilocybin less than thirty milligrams displayed the same improvement in symptoms as people who got doses more than thirty-five”
Outcome data from more than 2,300 regulated psilocybin clients suggest a threshold rather than a linear dose-response, challenging the assumption that higher doses yield greater benefit.
MICRODOSING AND EXPECTANCY [31:00]
“There's strong evidence now that microdosing is primarily a placebo effect.”
Placebo-controlled studies show benefit tracks what participants believed they received rather than what they actually took, useful context when patients ask about microdosing.
CHAPTERS:
00:00 – Introduction: Is the Experience the Medicine?
02:00 – From Basel and Zurich to Psilocybin and Synaptic Plasticity
07:30 – Psychedelic Research and Policy at CU Anschutz
10:30 – Functional Unblinding and the Search for Objective Endpoints
15:00 – Facilitator Support, Placebo Response, and Predictive Biomarkers
20:00 – Building Safety Into Colorado's Regulated Psilocybin Services
24:30 – Real-World Outcomes From Colorado and Oregon Psilocybin Clients
28:00 – Dose Thresholds, MEQ-30 Scores, and the Evidence on Microdosing
32:00 – Running Schedule I Research: Regulation, Funding, and INDs
36:30 – Safety Signals: Psychosis, Suicidality, and Adverse Event Follow-Up
43:00 – Blocking the 5-HT2A Receptor: Is the Trip Necessary?
47:30 – Cost, Access, and Shorter-Acting Psychedelics
50:30 – Receptor Promiscuity and Non-Hallucinogenic Compounds
53:30 – The Role of Psychotherapy in Psychedelic Treatment
59:30 – Definium's DT120: Phase III Data, Payer Realities, and Dose Selection
01:07:00 – Beckley Atai's 5-MeO-DMT and Other Short-Acting Compounds
01:09:30 – Clinical Takeaways
LINKS:
Full transcript and show notes:
https://www.psychiatrist.com/jcp/ep27-psychedelic-research-academic-medical-center-scott-thompson/
Journal of Clinical Psychiatry
https://www.psychiatrist.com/jcp/
Publisher of peer-reviewed research discussed in this episode.
Dr. Scott Thompson – LinkedIn
https://www.linkedin.com/in/scott-thompson-241a1a15/
Harnessing Psilocybin (Hesselgrave et al., PNAS, 2021)
https://doi.org/10.1073/pnas.2022489118
Dr. Thompson's mouse study showing psilocybin's antidepressant-like effects persisted despite 5-HT2A receptor blockade.
Colorado Natural Medicine Program
https://dpo.colorado.gov/NaturalMedicine
State program for regulated psilocybin services discussed in this episode.
Definium Therapeutics
https://definiumtx.com
Developer of DT120, the LSD formulation with phase III results in MDD and GAD.
#Psilocybin #PsychedelicMedicine #LSD #Neuroplasticity #FunctionalUnblinding
Thirty Years of the DCPR with Jenny Guidi, PsyD, PhD
2026/10/20
Jenny Guidi, PsyD, PhD, associate professor of clinical psychology at the University of Bologna and director of psychometric and clinimetric studies at Massachusetts General Hospital, joins host Ben Everett, PhD, to discuss her new systematic review in The Journal of Clinical Psychiatry. The review examines more than 30 years of research on the Diagnostic Criteria for Psychosomatic Research (DCPR), covering all 14 DCPR syndromes across 96 studies.
Traditional psychiatric diagnosis can overlook psychosocial factors that shape the course and outcome of medical illness. Dr. Guidi explains why DCPR syndromes were found more often than formal psychiatric diagnoses in many clinical settings, how demoralization differs from major depressive disorder and why that distinction changes treatment, and how allostatic overload links a patient's lived experience to measurable biological change. The conversation closes with practical considerations for bringing the semi-structured DCPR interview into routine clinical care.
🎯 KEY EPISODE HIGHLIGHTS:
🔍 WHAT STANDARD PSYCHIATRIC ASSESSMENT CAN MISS [09:39]
“Our results suggested that the DCPR captured distinct clinical phenomena rather than merely symptomatic manifestations or attenuated forms of psychiatric disorders.”
Many medically ill patients with meaningful psychological distress meet no psychiatric diagnostic category, yet DCPR syndromes can identify them and inform prognosis and treatment.
💊 WHEN AN ANTIDEPRESSANT IS THE WRONG TOOL [20:30]
“On the other hand, if you misdiagnose demoralization as major depression, you are likely to prescribe unnecessary pharmacological treatment for what is essentially a psychological problem.”
Recognizing demoralization redirects care toward psychotherapeutic approaches such as well-being therapy rather than medication with no evidence of benefit.
🧬 BIOGRAPHY WRITTEN INTO BIOLOGY [24:06]
“The concept of allostatic overload provides a theoretical bridge between biography and biology.”
Allostatic overload gives clinicians a measurable way to connect chronic stress and life events to changes across multiple biological systems.
CHAPTERS:
00:00 – Introduction and Dr. Guidi's Path to the DCPR Review
05:00 – What the DCPR Detect Beyond DSM and the 2017 Revision
09:16 – DCPR Syndromes Across Cardiology, CL Psychiatry, and Primary Care
14:32 – Distinguishing Demoralization From Major Depression
18:08 – Recognizing and Treating Demoralization
23:03 – Allostatic Overload: Where Biography Meets Biology
29:02 – Bringing the DCPR Into Routine Clinical Practice
LINKS:
Full transcript and show notes:
https://www.psychiatrist.com/jcp/ep26-thirty-years-dcpr-psychosomatic-research-jenny-guidi/
Journal of Clinical Psychiatry
https://www.psychiatrist.com/jcp/
Publisher of peer-reviewed research discussed in this episode.
Thirty Years of the Diagnostic Criteria for Psychosomatic Research (DCPR): A Systematic Review and Discussion of Clinical Implications
https://www.psychiatrist.com/jcp/Thirty-years-Diagnostic-Criteria-Psychosomatic-Research-systematic-review
Dr. Guidi's systematic review of all 14 DCPR syndromes across 96 studies, the focus of this episode.
The Demoralization Construct in Clinical Practice and Research (de Figueiredo)
https://www.psychiatrist.com/jcp/demoralization-construct-clinical-practice-research/
Companion commentary on distinguishing demoralization from depression, discussed in the episode.
Biography Inscribed in Biology (Horwitz)
https://www.psychiatrist.com/jcp/biography-biology-diagnostic-criteria-psychosomatic-research-embodiment-lived-experience/
Companion commentary on allostatic overload and the embodiment of lived experience.
Dr. Jenny Guidi - LinkedIn
https://www.linkedin.com/in/jenny-guidi-psyd-phd/
#DCPR #Demoralization #AllostaticOverload #PsychosomaticMedicine #Clinimetrics
Bonus Episode: Lessons from Early Adopters of XT in Schizophrenia with Ilan Melnick, MD
2026/10/13
In this bonus episode, host Ben Everett, PhD, reconnects with Ilan Melnick, MD, chief medical officer of Passageway, a South Florida forensic community control program, who also maintains a private concierge practice. Dr. Melnick chaired a JCP consensus panel of early adopters of xanomeline-trospium chloride (XT), and nearly two years after approval, he shares what clinicians have learned putting this first-in-class muscarinic agent into everyday practice.
Unlike dopamine D2 blockers, XT activates M1 and M4 muscarinic receptors to lower presynaptic dopamine, while trospium limits peripheral cholinergic effects. The conversation covers EMERGENT trial findings on positive, negative, and general psychopathology symptoms; early use in first-episode psychosis; titration to maintenance doses; prophylactic ondansetron and empty-stomach dosing; distinguishing cholinergic from anticholinergic adverse events; class-specific cross-titration; and antipsychotic dose sparing. Dr. Melnick also reviews two new Psych Congress posters: a real-world prescriber survey and a post hoc analysis of EMERGENT-5 examining GI side effects and treatment retention.
🎯 KEY EPISODE HIGHLIGHTS:
💊 ONDANSETRON BEFORE NAUSEA STARTS [31:00]
“One of the things we know about ondansetron is that it's a better preventer than it is a fixer.”
Prophylactic ondansetron at initiation is a simple step that can prevent early GI-related discontinuation.
⚖️ CHOLINERGIC OR ANTICHOLINERGIC? [36:00]
“If they're cholinergic in nature, go up to the one twenty-five. But if they're anticholinergic in nature then we have to see what other medicines are causing that extra anticholinergic effect.”
Identifying the type of adverse event determines whether to titrate up or review concomitant medications such as OTC sleep aids.
📈 STALLING AT 100 MG AND DROPOUT [49:41]
“So those that stay there and don't move up to the 125 milligram dose ended up usually dropping out due to higher GI issues.”
A post hoc EMERGENT-5 analysis suggests that titrating to the higher dose may support retention rather than threaten it.
CHAPTERS:
00:00 – Introduction: Revisiting the XT Consensus Panel
02:04 – Forensic Community Care and a Concierge Practice
05:26 – From Postsynaptic Blockade to Presynaptic Modulation
08:34 – M1/M4 Agonism and the Role of Trospium Chloride
13:03 – EMERGENT Trial Results and Early Cognitive Benefits
18:17 – Inside the Panel: Early Adopters and Experiential Evidence
22:35 – Early Use in First-Episode Psychosis and Dose Titration
28:28 – Patient Selection and Prophylactic Ondansetron
31:47 – Empty-Stomach Dosing and Cholinergic vs Anticholinergic Effects
37:15 – Cross-Titrating From Dones, Pines, and Partial Agonists
40:33 – Antipsychotic Dose Sparing, the ARISE Trial, and LAIs
44:17 – Psych Congress Poster: Real-World Prescriber Survey
49:07 – EMERGENT-5 Retention Data and the Future of Muscarinics
LINKS:
Full transcript and show notes:
https://www.psychiatrist.com/jcp/ep25-lessons-early-adopters-xt-schizophrenia-ilan-melnick/
Journal of Clinical Psychiatry
https://www.psychiatrist.com/jcp/
Publisher of peer-reviewed research discussed in this episode.
Real-World Implementation of Xanomeline-Trospium in Schizophrenia: A Consensus Panel Report
https://www.psychiatrist.com/jcp/real-world-implementation-xanomeline-trospium-schizophrenia-consensus-report/
The JCP consensus panel report chaired by Dr. Melnick and discussed throughout this episode.
Dr. Ilan Melnick - LinkedIn
https://www.linkedin.com/in/ilan-melnick-516b4468/
#Schizophrenia #XanomelineTrospium #MuscarinicAgonist #FirstEpisodePsychosis #Psychopharmacology
A Trauma Expert's View on Psychedelic Medicine with Steven Berkowitz, MD
2026/10/06
In this episode of the JCP Podcast, host Dr. Ben Everett speaks with Dr. Steven Berkowitz, Professor of Psychiatry at the University of Colorado School of Medicine and Director of the Stress, Trauma, and Adversity Research and Treatment (START) Center at CU Anschutz. Drawing on a career spanning the Yale Child Study Center, Penn, and CU, Dr. Berkowitz discusses how childhood trauma shapes psychiatric illness across the lifespan and what that means for early intervention, assessment, and treatment.
The conversation covers the neurobiology of early maltreatment, the development and outcomes of the CFTSI early intervention model, the debate over developmental trauma disorder and complex PTSD, and how trauma presents differently in autistic youth. Dr. Berkowitz also addresses treatment sequencing for comorbid substance use and ADHD, the central role of sleep in trauma care, sensory processing deficits in children in the child welfare system, and the scientific and ethical questions that would need to be answered before psychedelic research could be extended to children and adolescents with PTSD.
🎯 KEY EPISODE HIGHLIGHTS:
🌱 WE CAN'T TREAT OUR WAY OUT OF THIS CRISIS [07:00]
“I really believe in prevention, and I think unfortunately, given our current set of circumstances, we're never gonna treat our way out of what is a mental health crisis in this country.”
Dr. Berkowitz frames pediatric trauma work as prevention, noting that most adults in outpatient psychiatric care carry a history of childhood trauma.
😴 TRAUMA PSYCHIATRY IS SLEEP PSYCHIATRY [25:42]
“Trauma psychiatry in many ways is about sleep psychiatry. The goal is to get people sleeping.”
Targeting nightmares and nighttime intrusive symptoms first may make it possible for patients to engage meaningfully in trauma therapy.
🧠 PSYCHOTHERAPY IS ESSENTIAL IN YOUTH PSYCHEDELIC RESEARCH [35:32]
“With kids, feeling is it's not even a question. We should absolutely be doing psychotherapy in these sessions as well as before and after.”
Any future psychedelic trials in children and adolescents will require extensive family preparation and integrated psychotherapy, raising design questions the field has yet to answer.
CHAPTERS:
00:00 – Introducing Dr. Steven Berkowitz
01:30 – Forensic Expert Work and Delayed-Onset PTSD
05:00 – Prevention and the Neurobiology of Childhood Trauma
11:00 – Developing the CFTSI Early Intervention Model
16:00 – Developmental Trauma, Complex PTSD, and the Limits of the DSM
19:30 – How Trauma Presents in Autistic Youth
23:30 – Sequencing Treatment for Substance Use, Comorbidities, and Sleep
26:30 – The START Center, Sensory Processing, and the “Trauma-Informed” Debate
32:00 – PTSD Pharmacotherapy and Psychedelic Research in Youth
LINKS:
Full transcript and show notes:
https://www.psychiatrist.com/jcp/ep24-trauma-expert-view-psychedelic-medicine-steven-berkowitz/
Journal of Clinical Psychiatry
https://www.psychiatrist.com/jcp/
Publisher of peer-reviewed research discussed in this episode.
Dr. Steven Berkowitz – LinkedIn https://www.linkedin.com/in/stevenberkowitz/
CU Anschutz START Center https://www.cuanschutz.edu/home Dr. Berkowitz's family-centered, lifespan trauma research and treatment center.
Child and Family Traumatic Stress Intervention (CFTSI) https://www.nctsn.org/interventions/child-and-family-traumatic-stress-intervention
Brief early intervention model for children and caregivers discussed in this episode.
#ChildTrauma #PTSD #CFTSI #TraumaPsychiatry #PsychedelicResearch
Six Decades of Schizophrenia Care with Nina Schooler
2026/09/22
In this episode of the JCP Podcast, Dr. Ben Everett speaks with Dr. Nina Schooler, a social psychologist whose career in psychiatric research spans more than six decades. Dr. Schooler began her work at the National Institute of Mental Health's Psychopharmacology Service Center in the early 1960s and has since contributed to landmark studies on antipsychotic treatment, maintenance therapy, tardive dyskinesia, long-acting injectables, negative symptoms, and coordinated specialty care for first-episode psychosis.
As the field increasingly looks toward a paradigm of meaningful functional recovery that goes beyond symptom control, this conversation traces how today's clinical standards, from dose-reduction strategies to the RAISE early-intervention model, emerged from decades of trial design, unexpected findings, and hard-won methodological lessons.
🎯 KEY EPISODE HIGHLIGHTS:
🔍 THE ACCIDENTAL DISCOVERY IN THE FIRST PLACEBO STUDY [12:30]
“the patients who'd been treated with placebo seemed in some ways to be doing better than the patients who had been treated with drug.”
A counterintuitive early finding shows how unblinding and differential attention, not the drug itself, can distort perceived treatment effects in psychiatric trials.
🚧 WHY THE SICKEST PATIENTS ARE MISSING FROM NEGATIVE SYMPTOM TRIALS [1:04:00]
“the patients we most want to include will not be included in the trial because participating in a clinical trial requires effort”
A structural recruitment paradox helps explain why decades of negative symptom trials have struggled to enroll the patients most affected by the condition.
🤝 SCHIZOPHRENIA CARE AS “A TEAM SPORT” [1:19:30]
“My sense of schizophrenia as a treatment target is that it's a team sport, and that it requires a team of people to engage with patients offering a range of treatments for which I see medication as the absolutely essential platform on which other things, can indeed build.”
After six decades in the field, this framing captures why no single intervention, medication or psychosocial, succeeds alone in treating schizophrenia.
CHAPTERS:
0:00 – Introduction: Six Decades of Schizophrenia Research
2:30 – Joining NIMH's Psychopharmacology Service Center in the 1960s
9:00 – Shifting Terminology and the Boundaries of a Schizophrenia Diagnosis
11:30 – A Social Psychologist's Lens on Early Treatment Outcomes
16:00 – Open Questions on Lifelong Treatment and Parallel VA Research
18:30 – The Hogarty-Goldberg Studies and the Two-by-Two Trial Design
27:30 – Expressed Emotion and the Camberwell Family Interview
32:30 – Controlled Trials Versus Real-World Adherence
34:00 – Tardive Dyskinesia and the Push to Lower Antipsychotic Doses
36:30 – Designing the Treatment Strategies in Schizophrenia Study
40:30 – Results: Medication's Value and a Young, Family-Involved Cohort
45:00 – Long-Acting Injectables: Adherence Myths and the PROactive Study
51:30 – Research Diagnostic Criteria for Tardive Dyskinesia and the AIMS Scale
56:30 – Negative Symptoms, Cognition, and the Risperidone Question
1:02:30 – The FDA Workshop and Consent Challenges in the CONSIST Study
1:06:00 – Digital Interventions, EMA, and Smartphone-Based Treatment
1:09:30 – Designing RAISE: A Cluster-Randomized Approach to First-Episode Care
1:15:30 – RAISE Results and the Challenge of Personalized, Team-Based Care
1:21:00 – From RAISE to SAMHSA: Scaling Coordinated Specialty Care
1:25:30 – Has RAISE Changed Community Practice?
1:28:00 – Toward Meaningful Functional Recovery: What Must Change Next
LINKS:
Full transcript and show notes:
https://www.psychiatrist.com/jcp/ep23-six-decades-schizophrenia-care-nina-schooler/
Journal of Clinical Psychiatry
https://www.psychiatrist.com/jcp/
Publisher of peer-reviewed research discussed in this episode.
Dr. Nina Schooler – LinkedIn
https://www.linkedin.com/in/nina-schooler-11022870/
NIMH – Recovery After an Initial Schizophrenia Episode (RAISE)
https://www.nimh.nih.gov/research/research-funded-by-nimh/research-initiatives/recovery-after-an-initial-schizophrenia-episode-raise
NIMH overview of the RAISE initiative and coordinated specialty care model discussed at length in this episode.
SAMHSA – Early Serious Mental Illness Treatment Locator
https://www.samhsa.gov/find-help/locators/esmi
Locator for coordinated specialty care programs, funded through the SAMHSA block grants described in this episode.
#Schizophrenia #TardiveDyskinesia #LongActingInjectables #FirstEpisodePsychosis #Psychopharmacology
The Regulatory Maze of Ketamine and Psychedelics with Benjamin Brody, MD
2026/09/08
Dr. Benjamin Brody, an inpatient psychiatrist who built and now directs one of the earliest hospital-based ketamine treatment programs, joins Dr. Ben Everett to unpack the regulatory maze surrounding ketamine and the psychedelics now approaching FDA approval. Dr. Brody traces how he moved generic racemic ketamine from an overlooked anesthetic sitting on the hospital pharmacy shelf to a formally sanctioned inpatient treatment, and explains why esketamine's REMS-regulated pathway looks nothing like the largely unregulated market for take-home ketamine.
As synthetic psilocybin nears a possible FDA decision and the field debates what role psychotherapy should play alongside these treatments, clinicians face fast-moving questions about safety monitoring, staffing, informed consent, and reimbursement. Drawing on his direct experience administering ketamine on the inpatient unit, Dr. Brody discusses self-escalation risk, the paradox reaction his team termed dysphoric dissociation, and what health systems should weigh before building a program of their own.
🎯 KEY EPISODE HIGHLIGHTS:
⚠️ THE NARROW LINE BETWEEN NEUROTROPHIC AND NEUROTOXIC [18:30]
“But at higher doses, it actually becomes neurotoxic and, you know, there's histopathological changes that can be seen.”
At therapeutic doses ketamine is safe and neurotrophic, but Dr. Brody warns that self-escalating doses can quickly cross into neurotoxic and bladder-damaging territory.
🧠 DEFINING DYSPHORIC DISSOCIATION [24:00]
“This is a dysphoric piece or a dysphoric reaction that is layered on top of the dissociative experience for this small minority of patients.”
Dr. Brody explains why his team coined a new clinical term to distinguish ketamine's rare, frightening paradox reaction from a psychedelic “bad trip,” and why naming it matters for informed consent.
🚫 THE CASE AGAINST TAKE-HOME KETAMINE [25:00]
“The unambiguous answer is no, I do not think this is a good idea.”
Citing self-escalation risk, a narrow therapeutic index, and a growing number of ketamine-associated deaths, Dr. Brody explains why he opposes direct-to-consumer telehealth ketamine prescribing.
CHAPTERS:
00:00 – From Creative Writing to the Inpatient Unit
02:30 – A Day in the Life of an Inpatient Psychiatrist
05:30 – How Dr. Brody Came to Believe in Ketamine
12:00 – Ketamine vs. Classical Psychedelics: A Different Mechanism
14:00 – Two Regulatory Worlds: Racemic Ketamine and REMS-Regulated Esketamine
17:30 – Safety Signals: Self-Escalation and Dysphoric Dissociation
24:30 – The Case Against Take-Home Ketamine
29:30 – Psychedelics Enter the Medical Mainstream
33:30 – What to Expect When Psilocybin Gets FDA Approval
39:00 – Staffing and Consent for Hours-Long Sessions
43:00 – Set and Setting: Lessons from Building a Ketamine Program
48:00 – Is This Psychotherapy? Defining the Clinician's Role
54:00 – What Surprised Dr. Brody About Implementation
57:00 – Advice for Health Systems and Reasons for Optimism
LINKS:
Full transcript and show notes:
https://www.psychiatrist.com/jcp/ep22-regulatory-maze-ketamine-psychedelics-benjamin-brody/
Journal of Clinical Psychiatry
https://www.psychiatrist.com/jcp/
Publisher of peer-reviewed research discussed in this episode.
How Do We Get Ketamine Safety Right? Three Questions From a Clinical Service
https://www.psychiatrist.com/jcp/how-do-we-get-ketamine-safety-right-3-questions-from-clinical-service/
Dr. Brody's 2025 JCP commentary on self-escalation, paradox reactions, and the regulatory gap between racemic ketamine and esketamine, discussed at length in this episode.
COMPASS Pathways – COMP360 Psilocybin for Treatment-Resistant Depression
https://compasspathways.com/our-work/comp360-psilocybin-treatment-in-trd/
The investigational psilocybin program discussed throughout the episode, including its phase 3 timeline and proposed psychological support model.
Dr. Benjamin Brody – LinkedIn
https://www.linkedin.com/in/benjamin-brody-md-3576bb4/
#Ketamine #Psychedelics #TreatmentResistantDepression #Psychopharmacology #REMS
From Screening to Treatment: Rethinking Suicide Risk with Elizabeth Ballard, PhD
2026/08/25
Dr. Elizabeth Ballard, Director of Psychology and Behavioral Research and Director of Pre-Doctoral Training at the National Institute of Mental Health's Experimental Therapeutics and Pathophysiology Branch, joins the JCP Podcast to trace the full arc of suicide risk assessment and treatment. Dr. Ballard helped develop the Ask Suicide Screening Questionnaire (ASQ) and was first co-author on the individual patient data meta-analysis establishing ketamine's rapid antisuicidal effect.
Suicide risk is assessed in some form during nearly every patient encounter, yet the tools clinicians use and the evidence behind current treatments remain works in progress. Dr. Ballard discusses the sensitivity-specificity trade-offs built into screening instruments, what ketamine research reveals about suicidality as distinct from depression, emerging biomarkers such as nocturnal wakefulness and electrophysiological signatures of hopelessness, and the ethical case for including suicidal patients in clinical research rather than excluding the population clinicians most need evidence for.
🎯 KEY EPISODE HIGHLIGHTS:
🩺 SCREENING IS A LIFE-OR-DEATH TRADE-OFF [11:00]
“This is literally a life or death situation, and so you don't want people slipping through the cracks that aren't getting identified.”
Ballard frames the sensitivity-specificity trade-off built into suicide screening tools like the ASQ as a stakes-defining design choice, not just a statistical one.
🎯 SUICIDE RISK IS MULTIFACTORIAL, SO WHERE DO YOU START [39:00]
“There's so many factors that lead somebody in a moment of crisis to think about ending their lives.”
Ballard argues clinicians can't treat every contributing factor at once, which is why her research isolates modifiable targets like hopelessness rather than suicide risk as a whole.
❤️ WHEN IN DOUBT, ASK [52:30]
“When in doubt, ask. There's no harm in asking.”
Ballard's single most actionable takeaway: approach suicide risk assessment with curiosity rather than treating it as a documentation exercise.
CHAPTERS:
00:00 – Introduction: Dr. Elizabeth Ballard's Path to Suicide Research
05:30 – Building and Calibrating the ASQ Screening Tool
12:30 – The 2018 AJP Ketamine Meta-Analysis: Pooling Individual Patient Data
17:30 – Disentangling Ketamine's Effect on Suicidality from Depression
20:30 – Ketamine's Response Trajectory and IV vs. Esketamine Comparison
25:30 – Nocturnal Wakefulness as a Warning Sign for Suicidal Ideation
31:00 – MEG and Electrophysiological Signatures of Suicide Risk
34:00 – Concordance Across Suicide Risk Assessment Scales
38:00 – Hopelessness as a Distinct, Modifiable Treatment Target
41:00 – Neurofeedback and Episodic Future Thinking at Neu Hope
45:00 – Ethically Including Suicidal Patients in Clinical Research
52:00 – Closing Clinical Takeaway: Asking with Curiosity
LINKS:
Full transcript and show notes:
https://www.psychiatrist.com/jcp/ep21-rethinking-suicide-risk-screening-treatment-elizabeth-ballard/
Journal of Clinical Psychiatry
https://www.psychiatrist.com/jcp/
Publisher of peer-reviewed research discussed in this episode.
Ask Suicide-Screening Questions (ASQ) Toolkit – NIMH
https://www.nimh.nih.gov/research/research-conducted-at-nimh/asq-toolkit-materials
Free NIMH toolkit for the screening instrument Dr. Ballard helped develop, discussed at length in this episode.
Dr. Elizabeth Ballard – LinkedIn
https://www.linkedin.com/in/elizabeth-ballard-943245350/
#SuicideRiskAssessment #Ketamine #SuicidePrevention #ClinicalResearchEthics #Hopelessness
Feeding the Mind: Metabolism in Psychiatry with David T. Liebers, MD, MPhil, MPP
2026/08/11
Dr. David T. Liebers, MD, MPhil, MPP, a research assistant professor of psychiatry at the NYU Grossman School of Medicine and a research psychiatrist at the Nathan Kline Institute, joins Dr. Ben Everett to explore metabolic psychiatry: the growing evidence linking mitochondrial function, bioenergetics, and whole-body metabolism to psychiatric illness. Building on a previous conversation about GLP-1 receptor agonists, this episode broadens the lens to ketogenic diet interventions, SGLT2 inhibitors, and metformin, tracing how each may support brain energetics in depression, schizophrenia, and bipolar disorder.
This conversation arrives as clinicians increasingly confront the metabolic burden of antipsychotic treatment alongside a widening evidence base for interventions originally developed for diabetes and heart failure. Dr. Liebers discusses recent trial data on ketogenic diets in serious mental illness, the mechanistic case for SGLT2 inhibitors as a psychiatric tool, expanding guidelines for metformin co-prescription, and why brain energetics may represent a legitimate and increasingly tractable therapeutic target, not a replacement for existing models of psychiatric illness, but an additional clinical perspective.
🎯 KEY EPISODE HIGHLIGHTS:
🏛️ THE “ERA OF FOOD AS MEDICINE” ISN’T NEW [12:30]
“We have now entered the era of food as medicine.”
Dr. Liebers traces today's food-as-medicine rhetoric back through nearly two centuries of psychiatric interest in diet's role in mental illness.
🧬 MITOCHONDRIAL DYSFUNCTION AS A TREATMENT TARGET [23:30]
“The big challenge, I think, is identifying those interventions that can reliably improve, metabolic function in a way that can be measured and is suitable for randomized trial designs that let us talk about causation.”
Dr. Liebers frames abnormal brain bioenergetics as a specific, measurable target for a subset of patients underserved by monoamine-based treatments.
⚖️ METFORMIN IS DRAMATICALLY UNDERUSED [55:30]
“I think ten to fifteen percent of the people that should be or would qualify under the new guidelines to get metformin are actually on it.”
Despite expanded 2025 consensus guidelines, Dr. Liebers' EHR data suggest most eligible patients are still not receiving metformin for antipsychotic-associated weight gain.
CHAPTERS:
00:00 – Introduction: Building on the GLP-1 Conversation
02:30 – An Unconventional Path to Metabolic Psychiatry
10:30 – Diet in the Asylum Era: A History of Food as Medicine
18:00 – Why Metabolism Returned to Scientific View
23:30 – Imaging Brain Energetics: Bridging Peripheral and Central Metabolism
28:30 – The Stanford Pilot Trial and the Abrams Follow-On RCT
36:00 – Adherence, Meal Delivery, and the Path to GLP-1s
39:30 – GLP-1 Receptor Agonists in Psychiatric Practice
41:30 – Discovering SGLT2 Inhibitors: A Resident's Chance Encounter
45:00 – The Ketogenic Mechanism Behind SGLT2 Inhibition
49:30 – Trial Emulation and the Empagliflozin Pilot Study
52:00 – Metformin's Expanding Role in Antipsychotic-Associated Weight Gain
56:30 – SGLT2 Inhibitors as a Complement to Ketogenic Therapy
61:30 – Toward a Whole-Person Model: Diet, Drugs, and Exercise
66:00 – Confronting the Treatment Gap: Underused Medications
68:00 – The Future of Metabolic Psychiatry: Integration, Not Revolution
71:30 – Closing Thoughts and Sign-Off
LINKS:
Full transcript and show notes:
https://www.psychiatrist.com/jcp/ep20-feeding-mind-metabolism-psychiatry-david-t-liebers/
Journal of Clinical Psychiatry
https://www.psychiatrist.com/jcp/
Publisher of peer-reviewed research discussed in this episode.
Dr. David T. Liebers – LinkedIn
https://www.linkedin.com/in/david-liebers-7b9706169/
Metabolic Mind
https://www.metabolicmind.org/
Patient and clinician resource on ketogenic and metabolic therapies for mental illness, recommended by Dr. Liebers in this episode.
The Emerging Role of GLP-1s in Psychiatry with Roger S. McIntyre, MD, FRCPC
Listen to a previous episode from April 21, 2026 covering GLP-1s in Psychiatry
#MetabolicPsychiatry #KetogenicDiet #SGLT2Inhibitors #Metformin #Mitochondria
Turning Stigma Into Stories of Hope with Aderonke Pederson, MD
2026/07/28
Dr. Aderonke Pederson, an assistant professor of psychiatry at Harvard Medical School and a psychiatrist in the Depression Clinical and Research Program at Massachusetts General Hospital, joins the JCP Podcast to discuss how contact-based storytelling can function as a clinical intervention for reducing mental illness stigma and medical mistrust.
Stigma and mistrust are measurable barriers that delay care-seeking and worsen outcomes, particularly among Black adults with moderate to severe depression or anxiety who are not currently engaged in mental health services. Dr. Pederson walks through the theoretical foundations of contact-based stigma reduction, her research on religiosity and heterogeneity within Black communities, and a self-administered, video-based mobile intervention now being tested in a randomized controlled trial to help close the engagement gap in primary care.
🎯 KEY EPISODE HIGHLIGHTS:
🧩 STIGMA AS A FUNDAMENTAL CAUSE OF HEALTH INEQUITIES [04:00]
“Stigma has been described as a fundamental cause of health inequities.”
Framing stigma this way means it remains a barrier to care even after every other access issue has been addressed.
🧬 WHY MEDICAL MISTRUST IS AN EXPECTED RESPONSE [05:30]
“We expect mistrust if we have historical factors that have led to that mistrust.”
Clinicians should validate and address the historical roots of mistrust before working to reduce it.
🗣️ NAMING STIGMA TO GET IT OUT OF THE ROOM [53:00]
“It's in the room with you, and the question is, do you acknowledge its presence?”
Recognizing stigma and mistrust as active forces in every clinical encounter is the first step to addressing them with patients.
CHAPTERS:
00:00 – Introduction: When Story Becomes Clinical Intervention
03:30 – Stigma as a Fundamental Cause of Health Inequities
07:30 – From Basic Science to Psychosocial Mechanism: Where Stigma Intervenes
12:00 – The Engagement Gap: Disparities in Depression and Anxiety Care
16:00 – Religiosity and the Limits of Past Contact on Future Stigma
19:30 – Beyond Racial Categories: Heterogeneity and Migration
23:30 – The Power of Story: Why Narrative Changes Behavior
27:30 – Contact Theory: From Allport to the Psychiatric Ward
33:00 – Fisher's Narrative Paradigm and the Neuroscience of Story
36:30 – Shared Identity vs. Story Content
39:00 – Designing the App: A User-Centered Approach
45:00 – Inside the Clinical Trial: Reaching a Hard-to-Enroll Population
49:00 – Primary Endpoints and the Question of Durability
52:30 – Closing Thought: Naming Stigma to Address It
LINKS:
Full transcript and show notes:
https://www.psychiatrist.com/jcp/ep19-turning-stigma-into-stories-hope-aderonke-pederson/
Journal of Clinical Psychiatry
https://www.psychiatrist.com/jcp/
Publisher of peer-reviewed research discussed in this episode.
Dr. Aderonke Pederson - LinkedIn
https://www.linkedin.com/in/aderonke-bamgbose-pederson-85345315/
#MentalHealthStigma #MedicalMistrust #HealthDisparities #DigitalTherapeutics #BlackMentalHealth
Bipolar Disorder in Pregnancy and Postpartum, with Crystal T. Clark, MD, MSc
2026/07/14
Dr. Crystal T. Clark, Associate Professor of Psychiatry at the University of Toronto and Canadian Research Chair in Reproductive Mental Health, joins the podcast to discuss the evidence-based management of bipolar disorder across pregnancy and the postpartum period. Dr. Clark, recently appointed head of the Department of Psychiatry at Women's College Hospital, has built her research career around closing the pharmacokinetic evidence gap for the mood stabilizers and antipsychotics used during pregnancy.
For decades, clinical practice around perinatal bipolar disorder was shaped by stigma and a lack of data, leaving many women counseled to discontinue effective treatment or avoid pregnancy altogether. Dr. Clark reviews how physiological changes in pregnancy alter the clearance of lamotrigine, lithium, and atypical antipsychotics, why postpartum tapering requires close monitoring, how the Mood Disorder Questionnaire can help distinguish bipolar from unipolar postpartum depression, and what her research reveals about racial disparities in diagnosis among Black women.
🎯 KEY EPISODE HIGHLIGHTS:
🚫 THE STIGMA OF DISCOURAGING PREGNANCY [05:30]
“No, there's no data. This is all stigma.”
Dr. Clark names outright that generations of counseling women with bipolar disorder against having children was never grounded in evidence.
🧪 LAMOTRIGINE CLEARANCE CAN JUMP 300% IN PREGNANCY [16:00]
“Elimination clearance really increases during pregnancy as much as two hundred to three hundred percent.”
This pharmacokinetic shift explains why patients on a stable lamotrigine dose can relapse mid-pregnancy despite full adherence.
📊 HIGHER BIPOLAR PREVALENCE AMONG BLACK POSTPARTUM WOMEN [48:30]
“When you looked at bipolar disorder, there was a higher prevalence amongst Black women.”
This diagnosis-level finding, rare in perinatal mental health research, points to a gap in how bipolar disorder is recognized in Black patients.
CHAPTERS:
00:00 – Introduction: A Career Built on Closing the Evidence Gap in Perinatal Bipolar Disorder
02:30 – The Discontinuation Era and the Stigma of Childbearing with Bipolar Disorder
08:30 – Reweighing the Risk-Benefit Calculus: Untreated Illness as Its Own Danger
13:30 – From Residency to Research: Uncovering the Pharmacokinetic Evidence Gap
18:00 – The Pharmacology of Pregnancy: How Lamotrigine, Lithium, and Antipsychotics Are Metabolized Differently
22:00 – From Algorithm to Practice: Applying and Titrating Lamotrigine Across Pregnancy and Postpartum
28:30 – Lithium in Pregnancy: Monitoring Levels and Revisiting the Ebstein's Anomaly Risk
35:00 – Atypical Antipsychotics: Quetiapine and Risperidone Pharmacokinetics
40:00 – Distinguishing Bipolar from Unipolar Postpartum Depression with the MDQ
45:30 – Racial Disparities in Perinatal Bipolar Disorder Diagnosis
50:00 – Designing a Postpartum Monitoring Plan for High-Risk Patients
54:00 – Future Directions: Formalizing the Lamotrigine Algorithm and Black Maternal Mental Health Research
57:30 – Closing Reflections: The Path Toward Diagnostic Precision
LINKS:
Full transcript and show notes:
https://www.psychiatrist.com/jcp/ep18-bipolar-disorder-pregnancy-postpartum-crystal-t-clark/
Journal of Clinical Psychiatry
https://www.psychiatrist.com/jcp/
Publisher of peer-reviewed research discussed in this episode.
Dr. Crystal T. Clark – LinkedIn
https://www.linkedin.com/in/crystalclarkmd/
Rates of Major Depressive Disorder and Bipolar Disorder in Black and White Postpartum Women (JCP, 2024)
https://www.psychiatrist.com/jcp/rates-major-depressive-bipolar-disorder-black-white-postpartum-women/
The 2024 study discussed at length in this episode's chapter on racial disparities in perinatal bipolar diagnosis.
A Comparison of Symptoms of Bipolar and Unipolar Depression in Postpartum Women (J Affect Disord, 2022)
https://pubmed.ncbi.nlm.nih.gov/35041868/
The MDQ-based screening study Dr. Clark walks through when discussing how to distinguish bipolar from unipolar postpartum depression.
#BipolarDisorder #PerinatalPsychiatry #Psychopharmacology #PostpartumPsychosis #MaternalMentalHealth
The Art of Deprescribing: A Framework for Ending Medication
2026/06/16
In this episode, Dr. Ben Everett is joined by Dr. Joseph F. Goldberg, clinical professor of psychiatry at the Icahn School of Medicine at Mount Sinai and deputy editor-in-chief of the Journal of Clinical Psychiatry. Dr. Goldberg recently completed his term as president of the American Society of Clinical Psychopharmacology (ASCP), during which he led a 45-member international task force that produced a landmark series of consensus statements on deprescribing psychotropic medications, the principal findings of which were published in JAMA Network Open.
The decision to stop a medication is among the most common—yet least formalized—clinical acts in psychiatry. Despite decades of prescribing guidance, the field has lacked systematic frameworks for determining when, why, and how to discontinue treatment. This episode examines the ASCP task force's Delphi methodology, the areas of consensus and expert disagreement, and the practical implications for managing polypharmacy, navigating discontinuation phenomena, counseling pregnant patients, and training the next generation of prescribers.
🎯 KEY EPISODE HIGHLIGHTS:
📋 MEDICINES AS EMPLOYEES: THE PERFORMANCE REVIEW FRAMEWORK [03:30]
“I often like to think of medicines like employees on a payroll, and from time to time, it's a good thing to do a performance review of everybody on the payroll and ask what's your job, and are you doing it well, and is your job still there, or is that niche no longer present?”
Dr. Goldberg's core framework reframes deprescribing as a structured, periodic clinical evaluation—shifting the default from indefinite continuation to deliberate reassessment.
⚠️ PSEUDOTREATMENT RESISTANCE: THE LAI LITMUS TEST [22:00]
“Up to eighty percent of people don't take their medicines as prescribed, and oftentimes that could be quite substantial. It does run the risk of erroneously concluding this drug didn't work for you.”
Before deprescribing in schizophrenia, the task force emphasizes ruling out non-adherence—including a strong recommendation to consider long-acting injectable antipsychotics as a diagnostic and therapeutic step.
🧠 THE PSYCHOLOGY OF STOPPING: MEDICATION AS TRANSITIONAL OBJECT [34:30]
“To say I'm gonna take away this tangible thing that's meant to alleviate your suffering could mean I think you're doing pretty well and you don't need this anymore. Or it could also mean I'm not sure you're really suffering as much as you think you are.”
The decision to deprescribe carries significant psychological weight for patients—and clinicians who overlook this dimension risk undermining therapeutic alliance and triggering distress independent of pharmacology.
CHAPTERS:
00:00 – Introduction and Defining Deprescribing
07:00 – Why Now: ASCP's Task Force and the Political Landscape
13:30 – Delphi Methodology: Consensus and Divergence
15:30 – The Lithium Overdose Dilemma: When Stopping Defies a Rule
20:00 – Adherence, Pseudotreatment Resistance, and Schizophrenia
25:30 – Complex Polypharmacy and Medication Performance Reviews
29:30 – Valproate and Women of Reproductive Potential
34:00 – The Psychology of Stopping: Medication Attachment and Placebo
37:30 – Long Half-Life Drugs and Auto-Tapering
40:30 – Discontinuation Phenomena, Brain Zaps, and Hyperbolic Tapering
45:30 – Pregnancy, Special Populations, and Relapse Risk
49:30 – Training Gaps and the Future of Deprescribing Education
LINKS:
Full transcript and show notes:
https://www.psychiatrist.com/jcp/ep17-art-deprescribing-framework-ending-medication-joseph-goldberg/
Journal of Clinical Psychiatry
https://www.psychiatrist.com/jcp/
Publisher of peer-reviewed research discussed in this episode.
Dr. Joseph Goldberg – LinkedIn
https://www.linkedin.com/in/joseph-goldberg-922b5317/
American Society of Clinical Psychopharmacology (ASCP)
https://www.ascpp.org/
The organization that convened the 45-member international deprescribing task force discussed in this episode.
ASCP Deprescribing Consensus Statement — JAMA Network Open
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2845497
The parent consensus paper on general principles of deprescribing psychotropic medications.
#Deprescribing #Psychopharmacology #Polypharmacy #MedicationManagement #ClinicalPsychiatry
Forty Years at the PTSD Frontier with Barbara O. Rothbaum, PhD
2026/06/02
EPISODE DESCRIPTION
Dr. Barbara O. Rothbaum, PhD, is a tenured professor in the Department of Psychiatry and Behavioral Sciences at Emory University School of Medicine, where she holds the Paul A. Janssen Chair in Neuropsychopharmacology. She is director of the Trauma and Anxiety Recovery Program, director of the Emory Healthcare Veterans Program, and as of 2025, science director of the Emory Center for Psychedelics and Spirituality. With more than 400 scientific papers and multiple books to her name, Dr. Rothbaum is one of the foremost authorities on PTSD treatment in the world. In this episode, she joins host Ben Everett to reflect on four decades at the frontier of PTSD research, from the earliest days of the field's recognition as a disorder to the cutting edge of psychedelic-assisted therapy and virtual reality exposure.
PTSD remains one of psychiatry's most consequential and undertreated conditions, affecting a substantial portion of combat veterans, survivors of sexual trauma, and countless others who have never received an accurate diagnosis. In this conversation, Dr. Rothbaum covers the evidence base for first-line trauma-focused therapies — prolonged exposure, cognitive processing therapy, and EMDR — and the intensive outpatient model that has dramatically improved treatment retention. She then turns to the stalled landscape of PTSD pharmacotherapy, her translational research combining MDMA with prolonged exposure, the emerging role of psilocybin and ketamine, and the evolution of virtual reality exposure therapy from her laboratory's 1993 pilot to the Brave Mind system now deployed across more than 50 VA health systems.
KEY EPISODE HIGHLIGHTS
🧠 PTSD TREATMENT IS ABOUT APPROACHING, NOT AVOIDING [09:00]
"There's no way to the other side of the pain except through it."
Dr. Rothbaum explains the core mechanism underlying all empirically supported PTSD therapies — and why avoidance is the central obstacle to recovery.
💊 SSRIs ARE NOT REALLY THE TREATMENT FOR PTSD [24:30]
"I personally will think of them like weak coffee for PTSD. Maybe you can get a little bit of effect, maybe on mood, maybe on thinking."
Despite being the only FDA-approved pharmacotherapy for PTSD, SSRIs fall well short of the evidence base for trauma-focused psychotherapy — and combination treatment offers no advantage.
🥽 VIRTUAL REALITY EXPOSURE THERAPY GIVES CLINICIANS TOTAL CONTROL [43:30]
"If my patient's not ready for turbulence, I can guarantee there won't be turbulence. When they are ready for turbulence, I can guarantee there will be turbulence."
From fear of heights to virtual Iraq and Afghanistan combat environments, VR allows therapists to precisely calibrate stimulus intensity — closing the gap between imaginal exposure and real-world treatment.
CHAPTERS
00:00 - Introduction and Guest Biography
03:30 - Career Origins: Starting with Edna Foa
05:30 - A Career at the Intersection of Therapy, Technology, and Pharmacology
08:00 - First-Line Psychotherapies: PE, CPT, and EMDR
13:30 - Comparing the Therapies: Evidence and Patient Fit
15:30 - The Emory Healthcare Veterans Program and the IOP Model
21:00 - Recognizing PTSD in Primary Care
23:30 - Pharmacotherapy: The Limits of SSRIs
27:30 - Recent Drug Development Setbacks: MDMA and Brexpiprazole
31:00 - Translational MDMA Research and Combining with Prolonged Exposure
37:30 - Lessons from Australia's MDMA Approval
39:00 - The Broader Psychedelic Landscape: Psilocybin, Ketamine, and Others
43:00 - Virtual Reality Exposure Therapy and the Brave Mind System
49:30 - Resilience, Hope, and the Future of PTSD Treatment
LINKS
Full transcript and show notes
https://www.psychiatrist.com/jcp/ep16-forty-years-ptsd-frontier-barbara-o-rothbaum/
Journal of Clinical Psychiatry
https://www.psychiatrist.com/jcp/
Dr. Barbara O. Rothbaum — LinkedIn
https://www.linkedin.com/in/barbara-rothbaum-9339546
Emory Healthcare Veterans Program
https://www.emoryhealthcare.org/lp/veterans-ptsd
The intensive outpatient program for post-9/11 veterans discussed throughout this episode.
Wounded Warrior Project — Warrior Care Network
https://www.woundedwarriorproject.org/programs/warrior-care-network
Funds the four IOP programs, including Emory's, discussed in the episode. No cost to veterans.
#PTSD #TraumaTherapy #MDMAAssistedTherapy #VirtualRealityTherapy #Veterans
Rethinking Postpartum Depression: Biology, Biomarkers, and New Treatments with Jennifer L. Payne, MD
2026/05/19
In this episode of the JCP Podcast, host Dr. Ben Everett speaks with Dr. Jennifer L. Payne, Professor of Psychiatry and Neurobehavioral Sciences and Vice Chair of Research at the University of Virginia, where she directs the Reproductive Psychiatry Research Program. Dr. Payne holds a joint appointment in obstetrics and gynecology and has spent her career at the intersection of basic neuroscience and clinical care in perinatal psychiatry. She is widely recognized for her work on the biological underpinnings of postpartum depression, including epigenetic biomarkers that prospectively predict risk, and for her clinical and research contributions to the development of GABAergic therapeutics — from brexanolone to zuranolone — that are reshaping how the field understands and treats this condition.
Postpartum depression affects roughly one in eight women following childbirth and remains one of the most underdiagnosed and undertreated conditions in medicine. Despite this, care has long defaulted to serotonergic antidepressants developed for major depression rather than agents designed around the biology of the postpartum period. In this episode, Dr. Payne explains why the precipitous drop in neuroactive steroids — particularly allopregnanolone — following delivery may be central to postpartum depression pathophysiology, how the GABA-A receptor is implicated in ways that are distinct from benzodiazepines, what the clinical proof-of-concept established by brexanolone means for the field, and why zuranolone's oral formulation is changing real-world access. Dr. Payne also discusses the epigenetic biomarker test her lab has developed with collaborator Dr. Zachary Kaminsky — work now moving toward FDA review — its ethical implications, and emerging parallels with premenstrual dysphoric disorder.
KEY EPISODE HIGHLIGHTS
🔬 PREDICTING POSTPARTUM DEPRESSION BEFORE IT STARTS [12:30]
"We can take blood in the third trimester, and we can say whether a woman is at high risk of developing postpartum depression by three months postpartum or at low risk."
Dr. Payne describes the epigenetic biomarker test developed with Dr. Zachary Kaminsky — replicated in six independent samples and now advancing toward FDA review — that identifies postpartum depression risk from a third-trimester blood draw, enabling preventive planning before symptoms emerge.
🧠 WHY BREXANOLONE IS NOT JUST A BENZODIAZEPINE [24:15]
"The benzodiazepines don't act on those extrasynaptic GABA receptors. So sometimes people have said to me that allopregnanolone and the new FDA-approved treatments for postpartum depression are really just a benzodiazepine, and that's not true."
Dr. Payne explains the critical mechanistic distinction between benzodiazepines (synaptic GABA-A binding) and neuroactive steroids (extrasynaptic GABA-A binding), clarifying why this difference matters for setting the brain's overall inhibitory tone — a distinction clinicians should be prepared to address with patients.
💊 ZURANOLONE: FOURTEEN DAYS, SUSTAINED RESPONSE [31:00]
"You take [zuranolone] for fourteen days, and you see response rates within three days, which again, is groundbreaking in terms of treating a depressive episode."
The shift from a 60-hour inpatient IV infusion to a 14-day oral course has transformed real-world feasibility. Dr. Payne reviews the clinical profile of zuranolone — including rapid onset, sedation considerations, breastfeeding questions, and the practical barriers that still limit access.
CHAPTERS
00:00 - Introduction and Guest Overview
02:45 - Scientific Origins: From Alzheimer's Disease to Postpartum Depression
06:30 - Why Postpartum Depression Is a Natural Model for Studying Depression Biology
08:00 - Screening, Underdiagnosis, and the Stigma Gap
09:30 - A Personal Account of Postpartum Depression and Advocacy
12:00 - Epigenetic Biomarkers: Predicting Risk Before Delivery
17:15 - Ethics, Autonomy, and the Case for a Predictive Blood Test
20:45 - Allopregnanolone and the Neuroactive Steroid System
23:30 - GABA-A Receptor Subtypes: Why Neuroactive Steroids Are Not Benzodiazepines
25:30 - DoD-Funded Research: Neuroactive Steroid Shunting and GABA-A Reconfiguration
29:30 - Brexanolone: Clinical Proof of Concept and Why It's No Longer Available
31:30 - Zuranolone: Mechanism, Practical Considerations, and Real-World Access
37:00 - PMDD as a Window into Shared Biology
39:30 - The GABAergic Hypothesis and the Future of Depression Subtypes
41:45 - Improving Screening and Educating OBGYNs
43:30 - Closing Remarks
LINKS
Full transcript and show notes
https://www.psychiatrist.com/jcp/ep15-rethinking-postpartum-depression-biology-biomarkers-jennifer-l-payne/
Journal of Clinical Psychiatry
https://www.psychiatrist.com/jcp/
Publisher of peer-reviewed research discussed in this episode.
National Pregnancy Registry for Antidepressants: https://womensmentalhealth.org/research/pregnancyregistry/antidepressants/
Biomarkers:
DNA methylation biomarkers prospectively predict both antenatal and postpartum depression: https://pubmed.ncbi.nlm.nih.gov/31843207/ Seeing the Future: Epigenetic Biomarkers of Postpartum Depression: https://pmc.ncbi.nlm.nih.gov/articles/PMC3857665/ Biomarker or pathophysiology? The role of DNA methylation in postpartum depression: https://pubmed.ncbi.nlm.nih.gov/24059792/
DOD Work in Segment II:
Metabolites of Progesterone in Pregnancy: Associations with Perinatal Anxiety: https://pmc.ncbi.nlm.nih.gov/articles/PMC10530426/ Neuroactive steroid biosynthesis during pregnancy predicts future postpartum depression: a role for the 3α and/or 3β-HSD neurosteroidogenic enzymes? https://pubmed.ncbi.nlm.nih.gov/39885361/
#PostpartumDepression #NeuroactiveSteroidsGABA #PerinataMentalHealth #Zuranolone #EpigeneticBiomarkers
Catching Cognitive Decline Early with Gary W. Small, MD
2026/05/05
Dr. Gary W. Small, Director of Behavioral Health Breakthrough Therapies at Hackensack Meridian Health and Professor of Psychiatry and Behavioral Health at the Hackensack Meridian School of Medicine, shares decades of clinical and research insight as he discusses the early detection and treatment of age-related cognitive decline. In this episode, he explores the continuum from normal aging to mild cognitive impairment to dementia, the real-world role of biomarkers, the promise and limits of current pharmacologic options, and the lifestyle interventions—especially aerobic exercise—with the strongest data behind them.
For most patients, cognitive decline unfolds gradually rather than suddenly, and the tools we have to detect it have outpaced the clarity of what to do next. Amyloid and tau assays, PET imaging, and APOE genotyping are increasingly available in primary care, but they raise as many questions as they answer, and disclosure can have real psychological consequences. Emerging evidence points to inflammation as a shared mechanism across many forms of decline, with anti-inflammatory drugs, curcumin, Omega-3s, sleep, and exercise all converging on the same target. Dr. Small frames a pragmatic, patient-centered approach: educate, contextualize tests, rule out reversible causes, treat symptomatically and aggressively when appropriate, and above all, move.
🧠 PROTECT, DON’T REPAIR [05:10]:
“It’s easier to protect a healthy brain rather than try to repair damage once it becomes extensive.”
Dr. Small articulates the case for early detection and prevention that has shaped his entire career.
🔬 TREAT THE PERSON, NOT THE SCAN [23:40]:
“You don’t treat a blood test, you treat a person. The good news with some of these early anti-amyloid drugs—the brain scan looks great. The bad news is, you’re going to forget this conversation.”
Dr. Small urges clinicians to resist reflexive, biomarker-driven treatment and instead anchor decisions in symptoms, goals, and risk–benefit conversations.
🏃 ONE RECOMMENDATION ABOVE ALL [44:50]:
“Physical exercise. There’s no question about it. We have the strongest data on it… Get on the treadmill, or even better, get outside and take a brisk walk or jog.”
Asked for a single, universal recommendation for brain health, Dr. Small is unequivocal.
CHAPTERS:
00:00 - Introducing Dr. Gary W. Small
02:20 - From Math to Metaphysics to Medicine
03:30 - Finding a Path into Psychiatry
04:20 - The Road to Geriatric Psychiatry and the Case for Early Detection
06:10 - Defining the Continuum: Normal Aging, MCI, and Dementia
09:00 - Interpreting Cognitive Complaints and the Weight of Information
12:30 - The Biology of Cognitive Decline and the Role of Inflammation
16:00 - What Is Lost When We Wait, and the Curcumin Story
20:20 - The PCP’s Role in Early Intervention and Lifestyle Counseling
22:10 - Biomarkers and Imaging: From Research Tool to Clinical Reality
25:00 - Biomarker vs. Surrogate Marker
27:20 - Differential Diagnosis and the Brain as a Rheostat
29:30 - Pharmacologic Treatment: Symptomatic vs. Disease-Modifying Drugs
32:40 - Lifestyle Modification and the Evidence for Aerobic Exercise
35:40 - Train, Don’t Strain: Exercising the Mind Socially
37:50 - Knowing When to Refer and Building Specialist Relationships
41:00 - Comorbid Conditions and the Whole-Person Approach
42:40 - Looking Ahead: The Next 5–10 Years
44:20 - The Single Best Recommendation: Physical Exercise
45:30 - Closing Thoughts
Links:
Full transcript and show notes: https://www.psychiatrist.com/jcp/ep14-early-detection-cognitive-decline-gary-w-small/
Journal of Clinical Psychiatry: https://www.psychiatrist.com/jcp/
Dr. Gary W. Small: https://www.hmhn.org/find-a-provider
#CognitiveDecline #AlzheimersDisease #GeriatricPsychiatry #BrainHealth
Podcast reviews
Read The Journal of Clinical Psychiatry Podcast podcast reviews
4.9 out of 5
13 reviews
★★★★☆
tunester1500 2026/10/10
Schizophrenia Care
I was rather concerned that Nina Schooler seemed to be upset that seriously ill patients that she knows have negative symptoms including abolition wer...
★★★★★
Michael Rancheros 2026/07/30
Best new psychiatry podcast
I’ve listened to a fair amount of psychiatry podcasts this is easily the best one by far to me. Always interesting, great guests. Keep it up JCP!! Lov...
★★★★★
DSM341 2026/05/12
Fantastic Reboot
J Clin Psych is back and better than ever, seriously!
★★★★★
Psych74 2026/01/10
Really insightful!
I love this podcast! The guests are luminaries in mental health, and the topics really move the needle on clinical practice. Thank you JCP!